Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Schenk

Showing results (361-370 of 411) with videos related to

Pageof 42
Sort By:
Plos One|May 9, 2015
Finasteride concentrations and prostate cancer risk: results from the Prostate Cancer Prevention TrialCindy H Chau, Douglas K Price, Cathee Till, et al.
Cancer Immunology Research|August 26, 2021
Spatial UMAP and Image Cytometry for Topographic Immuno-oncology Biomarker DiscoveryNicolas A Giraldo, Sneha Berry, Etienne Becht, et al.
Nature Communications|August 12, 2020
The varied sources of faculae-forming brines in Ceres' Occator crater emplaced via hydrothermal brine effusionJ E C Scully, P M Schenk, J C Castillo-Rogez, et al.
Journal of Cancer Survivorship : Research and Practice|October 10, 2020
Feasibility of a behavioral intervention using mobile health applications to reduce cardiovascular risk factors in cancer survivors: a pilot randomized controlled trialEric J Chow, David R Doody, Chongzhi Di, et al.
Prostate Cancer and Prostatic Diseases|July 20, 2016
A diagnosis of prostate cancer and pursuit of active surveillance is not followed by weight loss: potential for a teachable momentM A Liss, J M Schenk, A V Faino, et al.
Plos Genetics|May 17, 2021
DEFECTIVE EMBRYO AND MERISTEMS genes are required for cell division and gamete viability in ArabidopsisChin Hong Lee, Nathaniel P Hawker, Jonathan R Peters, et al.
ESMO Open|May 14, 2024
Evaluation of the inflammation-based modified Glasgow Prognostic Score (mGPS) as a prognostic and predictive biomarker in patients with metastatic colorectal cancer receiving first-line chemotherapy: a post hoc analysis of the randomized phase III XELAVIRI trial (AIO KRK0110)M Boukovala, D P Modest, I Ricard, et al.
The Journal of Urology|October 26, 2019
African American Race is Not Associated with Risk of Reclassification during Active Surveillance: Results from the Canary Prostate Cancer Active Surveillance StudyJeannette M Schenk, Lisa F Newcomb, Yingye Zheng, et al.
The Journal of Urology|January 18, 2020
Reply by AuthorsJeannette M Schenk, Lisa F Newcomb, Yingye Zheng, et al.
The Journal of Urology|November 6, 2020
Reply by AuthorsJ M Schenk, L F Newcomb, Y Zheng, et al.
Pageof 42

Showing results (361-370 of 411) with videos related to

Sort By:
Pageof 42
Plos One|May 9, 2015
Finasteride concentrations and prostate cancer risk: results from the Prostate Cancer Prevention TrialCindy H Chau, Douglas K Price, Cathee Till, et al.
Cancer Immunology Research|August 26, 2021
Spatial UMAP and Image Cytometry for Topographic Immuno-oncology Biomarker DiscoveryNicolas A Giraldo, Sneha Berry, Etienne Becht, et al.
Nature Communications|August 12, 2020
The varied sources of faculae-forming brines in Ceres' Occator crater emplaced via hydrothermal brine effusionJ E C Scully, P M Schenk, J C Castillo-Rogez, et al.
Journal of Cancer Survivorship : Research and Practice|October 10, 2020
Feasibility of a behavioral intervention using mobile health applications to reduce cardiovascular risk factors in cancer survivors: a pilot randomized controlled trialEric J Chow, David R Doody, Chongzhi Di, et al.
Prostate Cancer and Prostatic Diseases|July 20, 2016
A diagnosis of prostate cancer and pursuit of active surveillance is not followed by weight loss: potential for a teachable momentM A Liss, J M Schenk, A V Faino, et al.
Plos Genetics|May 17, 2021
DEFECTIVE EMBRYO AND MERISTEMS genes are required for cell division and gamete viability in ArabidopsisChin Hong Lee, Nathaniel P Hawker, Jonathan R Peters, et al.
ESMO Open|May 14, 2024
Evaluation of the inflammation-based modified Glasgow Prognostic Score (mGPS) as a prognostic and predictive biomarker in patients with metastatic colorectal cancer receiving first-line chemotherapy: a post hoc analysis of the randomized phase III XELAVIRI trial (AIO KRK0110)M Boukovala, D P Modest, I Ricard, et al.
The Journal of Urology|October 26, 2019
African American Race is Not Associated with Risk of Reclassification during Active Surveillance: Results from the Canary Prostate Cancer Active Surveillance StudyJeannette M Schenk, Lisa F Newcomb, Yingye Zheng, et al.
The Journal of Urology|January 18, 2020
Reply by AuthorsJeannette M Schenk, Lisa F Newcomb, Yingye Zheng, et al.
The Journal of Urology|November 6, 2020
Reply by AuthorsJ M Schenk, L F Newcomb, Y Zheng, et al.
Pageof 42